FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive non-small cell lung cancer

FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive non-small cell lung cancer

http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpe...

Source: FDA Center for Drug Evaluation and Research - What's New - September 21, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Lung Cancer | Non-Small Cell Lung Cancer